Furkan Ceylan

Prognostic ımpact of the modified Ryan tumor regression score in gastric and GEJ adenocarcinomas treated with neoadjuvant FLOT regimen

Mehmet Akif Parlar, BURAK BİLGİN, Bülent Yalçın, Efnan Algın et autres

tr (code pays fourni par la source)

Prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer: a retrospective cohort study

Furkan Ceylan, Serhat Sekmek, Ateş Kutay Tenekeci, Safa Can Efil et autres

BACKGROUND: The glucose-to-lymphocyte ratio (GLR) has recently gained attention as a composite biomarker reflecting systemic inflammation and metabolic dysregulation. While its prognostic value has been reported in various malignancies, its clinical utility in endometrial cancer remains unknown. This study aimed to evaluate …

tr, ca (code pays fourni par la source)

Evaluation of the Cellsway Microfluidic CTC Enrichment and Identification Platform for CTC Detection in Metastatic NSCLC

Ebru Özgür, Ayça Çırçır, B. Dogan, Sebnem M. Sahin et autres

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Standard tissue biopsies are invasive and unsuitable for repeated monitoring. Liquid biopsy technologies, particularly circulating tumor cell (CTC) analysis, offer a …

tr, ag (code pays fourni par la source)

Rare Adult-Onset Nasopharyngeal Botryoid Embryonal Rhabdomyosarcoma: A Case Report and Review of Literature

Furkan Ceylan, Ateş Kutay Tenekeci, A. Unal, Esin Kotiloğlu Kara et autres

Botryoid embryonal rhabdomyosarcoma (RMSs) is a rare malignant tumor typically seen in children, with common sites including the vagina, bladder, and nasopharynx.Its occurrence in adults, is extremely rare, with a very limited number of cases in the nasopharynx.This case report highlights the …

tr (code pays fourni par la source)

649eP Real-world survival outcomes in metastatic lobular breast cancer treated with CDK4/6 inhibitors and endocrine therapy: A multicenter retrospective study

E. Yildirim, Furkan Ceylan, S. Gokdere, Efnan Algın et autres

tr (code pays fourni par la source)

2079eP The NLA score as a prognostic biomarker in advanced driver-negative NSCLC treated with immunotherapy-based strategies

Furkan Ceylan, Safa Can Efil, Ateş Kutay Tenekeci, Didem Şener Dede et autres

tr, us (code pays fourni par la source)

Predicting survival outcomes in advanced pancreatic cancer using machine learning methods

İsmet Seven, Canay Caliskan, Fahriye Tuğba Köş, Hilal Arslan et autres

The prognosis for pancreatic cancer (PC) is poor, with a 5-year survival rate of approximately 10%. Methods such as machine learning (ML) can facilitate prognostic assessments by examining complex patterns in patient data that may not be discernible with traditional methods. The …

tr (code pays fourni par la source)

Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapy

Satı Coşkun Yazgan, Kamil Kayaş, Çağatay Arslan, Caner Kapar et autres

BACKGROUND: Prostate-specific membrane antigen (PSMA) is a key target in metastatic castration resistance prostate cancer (mCRPC). Enzalutamide, an androgen receptor pathway inhibitor (ARPi), increases PSMA expression, potentially enhancing 177Lu-PSMA-617 radioligand therapy. This study evaluates the impact of prior ARPi (enzalutamide vs abiraterone …

tr, us (code pays fourni par la source)

Comprehensive management strategies for amivantamab-induced toxicities and review of the literature

Furkan Ceylan, Gamze Sönmez, Ateş Kutay Tenekeci, A. Unal et autres

BackgroundLung cancer is a leading cause of cancer-related deaths, with Non-Small Cell Lung Cancer (NSCLC) comprising 85-90% of cases, most commonly adenocarcinoma. Key mutations include EGFR Exon 19 deletions and Exon 21 L858R. While third-generation TKIs like osimertinib, lazertinib, and aumolertinib are …

tr, gb (code pays fourni par la source)

Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer

Furkan Ceylan, Didem Şener Dede, Safa Can Efil, Ateş Kutay Tenekeci et autres

Background/aim: Perioperative FLOT is considered the gold standard treatment for locally advanced gastric cancer. However, in the adjuvant setting, chemotherapy intolerance has brought de-escalation strategies to the forefront as an important area of research. This study aimed to compare the efficacy of …

tr, kh (code pays fourni par la source)

Enhancing outcomes in mCRPC: The impact of androgen receptor inhibitor sequencing before ¹⁷⁷Lu-PSMA-617 therapy.

Coşkun Yazgan, Kamil Kayaş, Cagatay Arslan, Caner Kapar et autres

e17068 Background: Prostate-specific membrane antigen (PSMA) is a key therapeutic target in metastatic castration-resistant prostate cancer (mCRPC). Elevated PSMA expression predicts the efficacy of ¹⁷⁷Lu-PSMA-617 radioligand therapy. Enzalutamide, an androgen receptor pathway inhibitor (ARPi), has been shown to upregulate PSMA expression. This …

tr, us (code pays fourni par la source)

Comparative efficacy of adjuvant FOLFOX versus FLOT following neoadjuvant FLOT in locally advanced gastric cancer.

Furkan Ceylan, Didem Şener Dede, Safa Can Efil, Ateş Kutay Tenekeci et autres

e16120 Background: Perioperative FLOT is the gold-standard treatment for locally advanced gastric cancer (LAGC). However, the tolerability of adjuvant chemotherapy poses challenges, with many patients unable to complete treatment due to toxicity. This study compared the efficacy of adjuvant FLOT and FOLFOX …

tr (code pays fourni par la source)